Tedopi is a dna vaccine commercialized by OSE Immunotherapeutics, with a leading Phase III program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 9 clinical trials, of which 5 were completed, 3 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Tedopi’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Tedopi is expected to reach an annual total of $44 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
OSE-2101 (EP-2101, Texopi, Tedopi) is under development for the treatment of non-small cell lung cancer, non-mucinous epithelial ovarian cancer and advanced or metastatic pancreatic ductal adenocarcinoma. It is administered subcutaneously. It acts by targeting carcinoembryonic antigen-related cell adhesion molecule 5, HER2, MAGE 2, MAGE3. It is based upon Memopi technology.
It was also under development for the treatment of colon cancer, triple negative breast cancer, mesothelioma, brain metastasis.
OSE Immunotherapeutics Overview
OSE Immunotherapeutics (OSE) is a biotechnology company that discovers and develops immunotherapy products against invasive and metastatic late-stage cancers. The company’s memopi technology is employed in studying the development of treatments for ovarian, colon, and breast cancer. It provides products such as tedopi and effi-7. OSE’s Effi-7 is in preclinical development and targets autoimmune diseases and transplantation. OSE’s tedopi stimulates cytotoxic killer T cells and relearns them to detect cancer cells to eliminate them. The company offers pipeline products such as OSE-172, OSE-703, FR104, and 0SE-127. It markets its products through its distribution network. OSE is headquartered in Nantes, Pays-de-la-Loire, France.
The company reported revenues of (Euro) EUR26.3 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of EUR10.4 million in FY2020. The operating loss of the company was EUR16.6 million in FY2021, compared to an operating loss of EUR19 million in FY2020. The net loss of the company was EUR16.9 million in FY2021, compared to a net loss of EUR16.6 million in FY2020.
For a complete picture of Tedopi’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.